From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Aptamer – “good visibility on its commercial pipeline going into the second half”. Really?

By Steve Moore | Tuesday 3 January 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


‘Novel Optimer binders to enable innovation in the life sciences industry’ group Aptamer (APTA) has issued a “Half Year Trading Update” emphasising that “2022 has seen significant progress for Aptamer with the investment in new facilities to create more capacity and an expanded team, especially in sales and marketing” and that it “has good visibility on its commercial pipeline going into the second half, including a further £1.0m of current signed orders, as well as contracts in negotiation and strong expressions of interest across all three business units… remains focused on delivering market expectations for the full year”. So what of a current share price response down almost 7% to 47.5p?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 21:56:37